Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

1454 - Ascites-derived circulating microRNAs as potential diagnostic biomarkers of gastric cancer-associated malignant ascites


30 Sep 2019


Poster Display session 3


Translational Research

Tumour Site


Hye Sook Han


Annals of Oncology (2019) 30 (suppl_5): v25-v54. 10.1093/annonc/mdz239


H.S. Han1, H.B. Chae1, J. Yun2, H.J. Kim3, S. Go3, W.S. Lee3, W.K. Bae4, S.H. Cho4, E. Song5

Author affiliations

  • 1 Department Of Of Internal Medicine, Chungbuk National University College of Medicine, 28644 - Cheongju/KR
  • 2 Department Of Pharmaceutical Engineering, College of Science Engineering, Cheongju University, 28503 - Cheongju/KR
  • 3 Department Of Internal Medicine, Gyeongsang National University School of Medicine, 52727 - Jinju/KR
  • 4 Department Of Internal Medicine, Chonnam National University Medical School, 61469 - Gwangju/KR
  • 5 Department Of Internal Medicine, Chonbuk National University Medical School, 54907 - Jeonju/KR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1454


Peritoneal carcinomatosis with malignant ascites is associated with dismal prognosis in gastric cancer. Malignant ascites is the most relevant body fluid in which to seek diagnostic biomarkers for peritoneal carcinomatosis. We aimed to identify and validate ascites-derived circulating microRNAs (miRNAs) that are differentially expressed between liver cirrhosis-associated benign ascites (LC-ascites) and gastric cancer-associated malignant ascites (GC-ascites).


MiRNA expression levels were investigated in three independent cohorts. Overall, 165 ascites samples (73 LC-ascites and 92 GC-ascites) were obtained from the National Biobank of Korea. Initially, microarrays were used to screen the expression levels of 2,006 miRNAs in the discovery cohort (n = 22). Subsequently, quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) analyses were used to validate the expression levels of selected miRNAs in the training (n = 70) and validation (n = 73) cohorts. In addition, the levels of carcinoembryonic antigen (CEA) were determined in the ascites samples.


A total of 36 miRNAs were identified as having the potential to discriminate GC-ascites from LC-ascites via microarray analyses. Expression levels of miR-574-3p, miR-181b-5p, miR-4481, and miR-181d were significantly lower in the GC-ascites samples than in the LC-ascites samples via qRT-PCR analyses, and miR-181b-5p showed the best diagnostic performance for GC-ascites (area under the curve [AUC] = 0.798 and 0.846 for the training and validation cohorts, respectively). The diagnostic performance of CEA for GC-ascites was improved if miR-181b-5p and CEA were analyzed together (AUC = 0.981 and 0.946 for the training and validation cohorts, respectively).


We identified ascites-derived circulating miRNAs capable of differentiating non-malignant ascites and GC-ascites, and demonstrated that the combined use of miR-181b-5p and CEA produces the optimal diagnostic yield.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


National Research Foundation of Korea (NRF).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.